company background image
543322

Glenmark Life Sciences BSE:543322 Stock Report

Last Price

₹429.30

Market Cap

₹52.6b

7D

-0.8%

1Y

-30.0%

Updated

08 Dec, 2022

Data

Company Financials +
543322 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends3/6

543322 Stock Overview

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.

Glenmark Life Sciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Glenmark Life Sciences
Historical stock prices
Current Share Price₹429.30
52 Week High₹637.70
52 Week Low₹375.00
Beta0
1 Month Change-1.62%
3 Month Change-1.49%
1 Year Change-30.04%
3 Year Changen/a
5 Year Changen/a
Change since IPO-42.62%

Recent News & Updates

Recent updates

Shareholder Returns

543322IN PharmaceuticalsIN Market
7D-0.8%-2.2%-0.3%
1Y-30.0%-5.1%5.0%

Return vs Industry: 543322 underperformed the Indian Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: 543322 underperformed the Indian Market which returned 5.2% over the past year.

Price Volatility

Is 543322's price volatile compared to industry and market?
543322 volatility
543322 Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement5.5%
10% most volatile stocks in IN Market8.9%
10% least volatile stocks in IN Market3.5%

Stable Share Price: 543322 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 543322's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20111,655Yasir Rawjeehttps://www.glenmarklifesciences.com

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management. It also provides Atovaquone, Remogliflozin, Teneligliptin, Zonisamide, and Adapalene.

Glenmark Life Sciences Limited Fundamentals Summary

How do Glenmark Life Sciences's earnings and revenue compare to its market cap?
543322 fundamental statistics
Market Cap₹52.60b
Earnings (TTM)₹4.18b
Revenue (TTM)₹20.36b

12.6x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
543322 income statement (TTM)
Revenue₹20.36b
Cost of Revenue₹10.06b
Gross Profit₹10.30b
Other Expenses₹6.12b
Earnings₹4.18b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)34.13
Gross Margin50.58%
Net Profit Margin20.54%
Debt/Equity Ratio0%

How did 543322 perform over the long term?

See historical performance and comparison

Dividends

4.9%

Current Dividend Yield

31%

Payout Ratio